Background Quantification of the disease burden caused by different risks informs
prevention by providing an account of health loss different to that provided by a disease-by-disease …

Background Health system planning requires careful assessment of chronic kidney disease
(CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-…

Background Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia
as well as blood pressure, body weight, and albuminuria in people with diabetes. We …

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are
the leading cause of global mortality and a major contributor to disability. This paper reviews …

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few
effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–…

Background : The burden of cardiovascular diseases (CVDs) remains unclear in many regions
of the world. Objectives : The GBD (Global Burden of Disease) 2015 study integrated data …

Background The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides
an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden …

1 Patel A; ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and
indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes …

Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial
infarction, ischaemic stroke, and the need for coronary revascularisation in people without …

Importance Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying
the levels of SBP is important to guide prevention policies and interventions. Objective To …